about
P2' Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran MoietyA Conserved Hydrogen-Bonding Network of P2 bis-Tetrahydrofuran-Containing HIV-1 Protease Inhibitors (PIs) with a Protease Active-Site Amino Acid Backbone Aids in Their Activity against PI-Resistant HIVIdentification of amino acid residues critical for LD78beta, a variant of human macrophage inflammatory protein-1alpha, binding to CCR5 and inhibition of R5 human immunodeficiency virus type 1 replicationA potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugsDevelopment of therapeutics for AIDS: structure-based molecular targeting.Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide.Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide.Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.[New HIV-1 protease inhibitors in development].EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium.Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 InfectionBenzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversalActivity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1sActive-site deformation in the structure of HIV-1 RT with HBV-associated septuple amino acid substitutions rationalizes the differential susceptibility of HIV-1 and HBV against 4'-modified nucleoside RT inhibitorsSpirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles[Structure-guided molecular-targeting approach for development of AIDS therapeutics]Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudineThe High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse TranscriptaseHIV-1 DNA-capture-seq is a useful tool for the comprehensive characterization of HIV-1 provirus
P50
Q27679177-CB1D21B1-3399-477D-81DE-4E1E890C1CE0Q27683486-83A23194-B890-4F64-A375-1F60A3B404DEQ28209188-309C6738-1D37-4246-A827-EDD46DD390D2Q28344457-5B5E5717-28EA-452A-A0CC-4ED5B2A6F180Q33248893-79048DA8-54DA-4355-A035-40F90D735B4EQ33592025-B67578CF-4D7D-43C5-B628-6F1423123622Q33781391-47EE7A3D-54EC-46C6-9526-E030FC1258F9Q35168976-291F8A7D-3735-4C8A-B194-D68F946E95B4Q36047851-84511E38-6328-4819-8106-9CBC11FD922CQ36108952-3A6B50D9-41FA-45F8-BB3D-6E8E7FCC3C4FQ36703042-22A86D88-4B68-44C4-AACD-2C49A55DACC2Q36878239-EA8D5481-95FB-47C8-840B-82F117CC1DAEQ37071732-FF0A4749-B504-4E1C-BA1B-70971A16EA99Q37405251-1F6B9F32-44C1-4EBC-9F47-0030B27F4408Q39202247-55A5B331-EE7E-4200-8332-E129788CAB42Q40053336-E58B11CA-9015-4BE1-A779-7EC5054605B8Q40281622-47709289-D205-4888-86C7-11D708F615E3Q42259598-83EB74C2-A441-4D5D-96EC-C98C201238B9Q43027916-CA4D17DA-ED03-47FC-B1E5-92B086A4EFBBQ43968316-F197D3C1-A32B-4003-BDF7-A510C434517DQ45000747-5EC471ED-1CD3-4FF9-A771-294C37B00356Q46784008-E46BB552-2F66-4B77-AC3E-6C34FC763A51Q47548606-05DC90D2-6F73-49E5-A505-1C3AD6627A08Q51802017-B47DA427-584A-48BB-BBAD-D1266F5E8282Q57072848-35C81248-AF3E-45BB-9624-582DEA5DEF97Q58565586-20079B90-230E-4D8E-B248-F225545AA2F3Q64082901-8F3540F9-5AD1-43AB-9045-AC181020195BQ64118424-46C5312C-6163-431D-AE95-B2D0669D74F6Q82222765-CC578B83-6DEB-44E3-A7A0-BC5887A01339Q85210608-5CDA1929-027F-48AC-99DC-C27F9C4E5392Q89810607-E61756B2-FFFD-47D6-A368-17AB8A76E598Q91264752-0EBE44A8-52F2-4D34-8D9D-C51CC6EC7F13Q92833135-D183B34C-8381-4655-9AA3-5076DB8D2C88
P50
description
researcher
@en
հետազոտող
@hy
name
Kenji Maeda
@ast
Kenji Maeda
@en
Kenji Maeda
@es
Kenji Maeda
@nl
Kenji Maeda
@sl
type
label
Kenji Maeda
@ast
Kenji Maeda
@en
Kenji Maeda
@es
Kenji Maeda
@nl
Kenji Maeda
@sl
prefLabel
Kenji Maeda
@ast
Kenji Maeda
@en
Kenji Maeda
@es
Kenji Maeda
@nl
Kenji Maeda
@sl
P106
P31
P496
0000-0002-9424-1491